Mar 23 |
Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares
|
Mar 19 |
Enliven Therapeutics announces $90M private placement to fund R&D activities
|
Mar 19 |
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
|
Mar 14 |
Enliven Therapeutics GAAP EPS of -$0.47
|
Mar 14 |
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
|
Feb 27 |
Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
|
Feb 12 |
Enliven Therapeutics Maybe Improving Kinase Inhibitors, But Too Early To Tell The Impact
|
Jan 3 |
Enliven Therapeutics Inc CFO Benjamin Hohl Sells 11,870 Shares
|